Published in Hepatitis Weekly, November 13th, 2000
RPI also presented results of pre-clinical studies of RPI's anti-hepatitis B ribozyme product candidates having demonstrated marked efficacy in animal models.
Results were reported from a single dose volunteer study as well as from multidose studies of Heptazyme...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.